Johnson & Johnson (JNJ): Raises 2026 EPS outlook as Q3 sales rise 5.9%
J&J raised its 2026 adjusted EPS outlook to $11.05-$11.15 as Q3 sales rose 5.9% to $25.4B, led by Innovative Medicine (+7.7%). Adjusted EPS of $2.59…
Home/Companies/Johnson & Johnson (JNJ)
Johnson & Johnson (JNJ)
1 take
All Centiview takes on Johnson & Johnson (ticker JNJ): earnings, deals and market news, newest first. Filed under Healthcare; region: US. Each take lists its sources. For information only, not advice.